|
JP2018076236A
|
|
Pharmaceutical composition for treating cancer
|
|
JP2018080114A
|
|
Anti-human VAP-1 monoclonal antibody
|
|
JP2018080113A
|
|
Treatment agent of cerebral infarction
|
|
JP2014114279A
|
|
Combination of therapeutic agents for ophthalmology which enhances effect of agent with binding affinity to albumin in aqueous humor
|
|
JP2007211011A
|
|
Method for producing 15-ketoprostaglandin e derivative
|
|
JP2006045231A
|
|
Method for producing prostaglandin derivative
|
|
JPH11343280A
|
|
Prostaglandin compound
|
|
JPH10287532A
|
|
Hair-growing agent
|
|
JPH107574A
|
|
Endothelin antagonist
|
|
JPH0987179A
|
|
Agent for ameliorating ophthalmic nerve disorder
|
|
JPH09100233A
|
|
Cornea-protective agent
|
|
JPH0848665A
|
|
Treating agent for disease in hepatic and biliary tract system
|
|
JPH07291866A
|
|
Treating agent for improving cerebral function
|
|
JPH0770054A
|
|
Biological antagonist and disease-treating preparation
|
|
JPH0672996A
|
|
Stabilization of prostanoic acid compound
|
